STOCK TITAN

[424B3] Medicus Pharma Ltd. Prospectus Filed Pursuant to Rule 424(b)(3)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B3
Rhea-AI Filing Summary

Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) is marketing a new structured note: “Autocallable Contingent Coupon Equity-Linked Securities Linked to the Worst Performing of Broadcom Inc. (AVGO) and Palo Alto Networks Inc. (PANW), due 26 Jan 2027.” The $1,000-denominated senior unsecured notes offer a contingent coupon rate of at least 10.25% p.a. (paid quarterly at ≥2.5625% per period) but only if, on the relevant valuation date, the worst-performing share closes at or above its coupon barrier of 59% of its initial level. Any skipped coupons can “catch up” if the barrier is later met, but coupons missed through final valuation are permanently forfeited.

Principal repayment is conditional. If the securities are not automatically called, holders receive at maturity:

  • $1,000 plus final coupon if the worst-performing share is ≥ its final buffer value (also 59% of initial).
  • A fixed number of worst-performing shares (or cash equivalent) if the final level is <59% of initial. This may be worth far less than $1,000 and could be $0 if the share price collapses.

Automatic early redemption (autocall) is possible on any of five quarterly dates starting 16 Oct 2025 if the worst-performing share is ≥ its initial level; investors then receive $1,000 plus the due coupon, ending the trade early and limiting upside.

Key initial terms (set 10 Jul 2025): AVGO initial $275.40, PANW initial $192.07; coupon/ buffer levels fixed at 59% of each. The preliminary estimated value on the pricing date is expected to be ≥$928.50, below the $1,000 issue price, reflecting distribution fees ($12.50) and internal funding spread.

Risks highlighted: (1) up to 100% capital loss if the worst performer drops >41%; (2) no guarantee of any coupon; (3) credit risk of both CGMHI and Citigroup Inc.; (4) liquidity risk—no exchange listing and discretionary secondary market only through CGMI; (5) potential conflicts as CGMI is issuer, underwriter, calculation agent and hedger; (6) complex U.S. tax treatment and potential 30% withholding for non-U.S. investors; (7) estimated value and secondary bid likely well below issue price due to hedging costs and bid–ask spread.

For investors seeking enhanced yield relative to plain-vanilla Citigroup senior debt, the note provides double-digit income potential and 41% downside buffer, but only by taking correlated single-stock equity risk, autocall truncation risk and issuer credit exposure. The security is therefore suitable solely for sophisticated investors who can tolerate equity-level volatility and illiquidity for up to 18 months.

Citigroup Global Markets Holdings Inc. (garantita da Citigroup Inc.) sta promuovendo una nuova nota strutturata: “Titoli azionari collegati a un coupon contingente autocallable legati alla performance peggiore tra Broadcom Inc. (AVGO) e Palo Alto Networks Inc. (PANW), con scadenza 26 gennaio 2027.” Le obbligazioni senior non garantite denominate $1.000 offrono un tasso di coupon contingente di almeno il 10,25% annuo (pagato trimestralmente con almeno il 2,5625% per periodo), ma solo se, alla data di valutazione rilevante, l’azione con la performance peggiore chiude a o sopra la soglia di coupon pari al 59% del valore iniziale. I coupon saltati possono essere recuperati se successivamente la soglia viene raggiunta, ma quelli persi alla valutazione finale sono definitivamente persi.

Il rimborso del capitale è condizionato. Se i titoli non vengono richiamati automaticamente, alla scadenza i possessori ricevono:

  • $1.000 più il coupon finale se l’azione peggiore è ≥ al valore di buffer finale (anch’esso il 59% del valore iniziale).
  • Un numero fisso di azioni della peggiore performance (o equivalente in contanti) se il valore finale è <59% del valore iniziale. Questo potrebbe valere molto meno di $1.000 e potenzialmente zero se il prezzo dell’azione crolla.

Il rimborso anticipato automatico (autocall) è possibile in cinque date trimestrali a partire dal 16 ottobre 2025 se l’azione peggiore è ≥ al valore iniziale; in tal caso gli investitori ricevono $1.000 più il coupon dovuto, terminando anticipatamente l’investimento e limitando il potenziale di guadagno.

Termini iniziali chiave (aggiornati al 10 luglio 2025): AVGO iniziale $275,40, PANW iniziale $192,07; livelli di coupon e buffer fissati al 59% per entrambi. Il valore stimato preliminare alla data di pricing è atteso ≥ $928,50, inferiore al prezzo di emissione di $1.000, riflettendo commissioni di distribuzione ($12,50) e spread di finanziamento interno.

Rischi evidenziati: (1) perdita fino al 100% del capitale se la peggiore azione scende oltre il 41%; (2) nessuna garanzia di coupon; (3) rischio di credito di CGMHI e Citigroup Inc.; (4) rischio di liquidità – nessuna quotazione in borsa e mercato secondario discrezionale solo tramite CGMI; (5) potenziali conflitti di interesse poiché CGMI è emittente, sottoscrittore, agente di calcolo e copertura; (6) trattamento fiscale USA complesso e possibile ritenuta del 30% per investitori non USA; (7) valore stimato e prezzo di mercato secondario probabilmente molto inferiori al prezzo di emissione a causa di costi di copertura e spread denaro-lettera.

Per gli investitori che cercano un rendimento superiore rispetto al debito senior plain-vanilla di Citigroup, la nota offre un potenziale di reddito a doppia cifra e un buffer di downside del 41%, ma solo assumendo rischi correlati a singole azioni, rischio di richiamo anticipato e rischio di credito dell’emittente. Il titolo è quindi adatto esclusivamente a investitori sofisticati in grado di tollerare volatilità azionaria e illiquidità per un periodo fino a 18 mesi.

Citigroup Global Markets Holdings Inc. (garantizado por Citigroup Inc.) está comercializando una nueva nota estructurada: “Valores ligados a acciones con cupón contingente autocancelable vinculados al peor desempeño entre Broadcom Inc. (AVGO) y Palo Alto Networks Inc. (PANW), con vencimiento el 26 de enero de 2027.” Los bonos senior no garantizados denominados en $1,000 ofrecen una tasa de cupón contingente de al menos 10.25% anual (pagada trimestralmente con ≥2.5625% por periodo), pero solo si, en la fecha de valoración correspondiente, la acción con peor desempeño cierra en o por encima de la barrera de cupón del 59% de su nivel inicial. Los cupones omitidos pueden recuperarse si la barrera se cumple posteriormente, pero los cupones no pagados en la valoración final se pierden permanentemente.

El reembolso del principal es condicional. Si los valores no son llamados automáticamente, los tenedores reciben al vencimiento:

  • $1,000 más el cupón final si la acción con peor desempeño está ≥ a su valor de buffer final (también 59% del inicial).
  • Un número fijo de acciones con peor desempeño (o equivalente en efectivo) si el nivel final es <59% del inicial. Esto puede valer mucho menos de $1,000 y podría ser $0 si el precio de la acción colapsa.

Redención anticipada automática (autocall) es posible en cualquiera de cinco fechas trimestrales a partir del 16 de octubre de 2025 si la acción con peor desempeño está ≥ a su nivel inicial; los inversionistas reciben entonces $1,000 más el cupón debido, terminando la operación anticipadamente y limitando el potencial de ganancia.

Términos iniciales clave (establecidos el 10 de julio de 2025): AVGO inicial $275.40, PANW inicial $192.07; niveles de cupón/barrera fijados en 59% para ambos. El valor estimado preliminar en la fecha de fijación de precio se espera sea ≥$928.50, por debajo del precio de emisión de $1,000, reflejando comisiones de distribución ($12.50) y el diferencial interno de financiamiento.

Riesgos destacados: (1) pérdida de capital hasta del 100% si el peor desempeño cae más del 41%; (2) sin garantía de cupón alguno; (3) riesgo crediticio de CGMHI y Citigroup Inc.; (4) riesgo de liquidez – sin cotización en bolsa y mercado secundario discrecional solo a través de CGMI; (5) posibles conflictos de interés ya que CGMI es emisor, suscriptor, agente de cálculo y coberturista; (6) tratamiento fiscal estadounidense complejo y posible retención del 30% para inversores no estadounidenses; (7) valor estimado y oferta secundaria probablemente muy por debajo del precio de emisión debido a costos de cobertura y diferencial de compra-venta.

Para inversores que buscan un rendimiento mejorado respecto a la deuda senior plain-vanilla de Citigroup, la nota ofrece potencial de ingreso de dos dígitos y un buffer de caída del 41%, pero solo asumiendo riesgos correlacionados con acciones individuales, riesgo de truncamiento por autocall y exposición al crédito del emisor. Por lo tanto, el título es adecuado únicamente para inversores sofisticados capaces de tolerar volatilidad a nivel de acciones e iliquidez por hasta 18 meses.

Citigroup Global Markets Holdings Inc. (Citigroup Inc. 보증)는 새로운 구조화 채권을 마케팅하고 있습니다: “Broadcom Inc.(AVGO)와 Palo Alto Networks Inc.(PANW) 중 최저 성과 주식에 연동된 자가상환형 조건부 쿠폰 주식 연계 증권, 만기 2027년 1월 26일.” $1,000 단위의 선순위 무담보 채권은 최소 연 10.25%의 조건부 쿠폰율(분기별 ≥2.5625% 지급)을 제공하지만, 해당 평가일에 최저 성과 주식이 초기 가격의 59%인 쿠폰 장벽 이상으로 마감할 경우에만 지급됩니다. 지급이 누락된 쿠폰은 이후 장벽 충족 시 회복 가능하지만, 최종 평가 시 누락된 쿠폰은 영구적으로 상실됩니다.

원금 상환은 조건부입니다. 증권이 자동 상환되지 않을 경우 만기 시 보유자는 다음을 받습니다:

  • 최저 성과 주식이 최종 버퍼 값(초기 가격의 59%) 이상일 경우 $1,000와 최종 쿠폰.
  • 최종 가격이 초기 가격의 59% 미만일 경우 최저 성과 주식 일정 수량(또는 현금 상당액). 이는 $1,000보다 훨씬 적을 수 있으며 주가 폭락 시 0이 될 수도 있습니다.

자가상환(오토콜)은 2025년 10월 16일부터 시작되는 5회 분기별 날짜 중 어느 날에나 가능하며, 최저 성과 주식이 초기 가격 이상일 경우 투자자는 $1,000과 해당 쿠폰을 받아 조기 종료되고 상승 잠재력은 제한됩니다.

주요 초기 조건(2025년 7월 10일 기준): AVGO 초기 $275.40, PANW 초기 $192.07; 쿠폰/버퍼 수준은 각각 59%로 고정. 가격 책정일의 예비 추정 가치는 $928.50 이상으로 예상되며, 이는 발행가 $1,000보다 낮습니다. 이는 배포 수수료($12.50)와 내부 자금 조달 스프레드를 반영한 것입니다.

강조된 위험: (1) 최저 성과 주식이 41% 이상 하락 시 최대 100% 자본 손실 가능; (2) 쿠폰 지급 보장 없음; (3) CGMHI 및 Citigroup Inc.의 신용 위험; (4) 유동성 위험 – 거래소 상장 없음, CGMI를 통한 임의의 2차 시장만 존재; (5) CGMI가 발행인, 인수인, 계산 대리인 및 헤지 담당자로서 잠재적 이해 상충; (6) 복잡한 미국 세금 처리 및 미국 외 투자자에 대한 30% 원천징수 가능성; (7) 헤지 비용 및 매수-매도 스프레드로 인해 추정 가치 및 2차 매도 호가가 발행가보다 훨씬 낮을 가능성.

평범한 Citigroup 선순위 채권 대비 수익률 향상을 원하는 투자자에게 이 노트는 두 자릿수 수익 잠재력과 41% 하락 방어막을 제공하지만, 단일 주식 관련 위험, 자동 상환 조기 종료 위험 및 발행인 신용 위험을 감수해야 합니다. 따라서 본 증권은 최대 18개월 동안 주식 수준의 변동성과 유동성 부족을 견딜 수 있는 숙련된 투자자에게만 적합합니다.

Citigroup Global Markets Holdings Inc. (garantie par Citigroup Inc.) commercialise une nouvelle note structurée : « Titres liés à des actions avec coupon conditionnel autocallable liés à la pire performance entre Broadcom Inc. (AVGO) et Palo Alto Networks Inc. (PANW), échéance 26 janvier 2027. » Les notes senior non garanties, d’une valeur nominale de 1 000 $, offrent un taux de coupon conditionnel d’au moins 10,25 % par an (payé trimestriellement à ≥2,5625 % par période), mais uniquement si, à la date d’évaluation pertinente, l’action la moins performante clôture à ou au-dessus de sa barrière de coupon fixée à 59 % de son niveau initial. Les coupons non versés peuvent être récupérés si la barrière est ensuite atteinte, mais les coupons manqués lors de l’évaluation finale sont définitivement perdus.

Le remboursement du capital est conditionnel. Si les titres ne sont pas automatiquement rappelés, les détenteurs reçoivent à l’échéance :

  • 1 000 $ plus le coupon final si l’action la moins performante est ≥ à sa valeur tampon finale (également 59 % du niveau initial).
  • Un nombre fixe d’actions de la pire performance (ou équivalent en espèces) si le niveau final est <59 % du niveau initial. Cela peut valoir bien moins que 1 000 $ et pourrait être nul si le cours de l’action s’effondre.

Le remboursement anticipé automatique (autocall) est possible à l’une des cinq dates trimestrielles à partir du 16 octobre 2025 si l’action la moins performante est ≥ à son niveau initial ; les investisseurs reçoivent alors 1 000 $ plus le coupon dû, mettant fin prématurément à l’opération et limitant le potentiel de gain.

Principaux termes initiaux (fixés au 10 juillet 2025) : AVGO initial 275,40 $, PANW initial 192,07 $ ; niveaux de coupon / tampon fixés à 59 % chacun. La valeur estimée préliminaire à la date de tarification devrait être ≥ 928,50 $, inférieure au prix d’émission de 1 000 $, reflétant les frais de distribution (12,50 $) et l’écart de financement interne.

Risques mis en avant : (1) perte en capital pouvant atteindre 100 % si la pire action chute de plus de 41 % ; (2) aucune garantie de coupon ; (3) risque de crédit de CGMHI et Citigroup Inc. ; (4) risque de liquidité – pas de cotation en bourse et marché secondaire discrétionnaire uniquement via CGMI ; (5) conflits potentiels d’intérêts car CGMI est émetteur, souscripteur, agent de calcul et couverturiste ; (6) traitement fiscal américain complexe et retenue à la source possible de 30 % pour les investisseurs non américains ; (7) valeur estimée et prix secondaire probablement bien inférieurs au prix d’émission en raison des coûts de couverture et du spread acheteur-vendeur.

Pour les investisseurs recherchant un rendement supérieur à celui de la dette senior classique de Citigroup, la note offre un potentiel de revenu à deux chiffres et une protection à la baisse de 41 %, mais uniquement en assumant un risque d’action individuelle corrélé, un risque de réduction par autocall et une exposition au risque de crédit de l’émetteur. Le titre est donc adapté uniquement aux investisseurs avertis capables de tolérer une volatilité au niveau des actions et une illiquidité pouvant durer jusqu’à 18 mois.

Citigroup Global Markets Holdings Inc. (garantiert von Citigroup Inc.) bringt eine neue strukturierte Note auf den Markt: „Autocallable Contingent Coupon Equity-Linked Securities, die an die schlechteste Performance von Broadcom Inc. (AVGO) und Palo Alto Networks Inc. (PANW) gekoppelt sind, Fälligkeit 26. Januar 2027.“ Die unbesicherten Senior Notes mit Nennwert $1.000 bieten einen bedingten Kupon von mindestens 10,25% p.a. (vierteljährlich gezahlt mit ≥2,5625% pro Periode), aber nur, wenn der Kurs der schlechtesten Aktie am jeweiligen Bewertungstag auf oder über der Kupon-Schwelle von 59% des Anfangswerts schließt. Ausgefallene Kupons können nachgeholt werden, falls die Schwelle später erreicht wird, bei endgültiger Bewertung verfallene Kupons sind jedoch dauerhaft verloren.

Die Rückzahlung des Kapitals ist bedingt. Werden die Wertpapiere nicht automatisch zurückgerufen, erhalten die Inhaber bei Fälligkeit:

  • $1.000 plus den letzten Kupon, wenn die schlechteste Aktie ≥ dem finalen Pufferwert (ebenfalls 59% des Anfangswerts) ist.
  • Eine feste Anzahl der schlechtesten Aktien (oder Baräquivalent), wenn der Endkurs <59% des Anfangswerts ist. Dieser Wert kann deutlich unter $1.000 liegen und bei einem Kurssturz sogar null betragen.

Automatische vorzeitige Rückzahlung (Autocall) ist an fünf vierteljährlichen Terminen ab dem 16. Oktober 2025 möglich, wenn die schlechteste Aktie ≥ dem Anfangswert ist; Anleger erhalten dann $1.000 plus den fälligen Kupon, wodurch das Investment vorzeitig endet und die Gewinnchancen begrenzt werden.

Wichtige Anfangsbedingungen (Stand 10. Juli 2025): AVGO Anfang $275,40, PANW Anfang $192,07; Kupon- und Pufferlevel sind jeweils auf 59% fixiert. Der vorläufig geschätzte Wert am Pricing-Tag wird voraussichtlich ≥$928,50 betragen, unter dem Ausgabepreis von $1.000, was Vertriebsgebühren ($12,50) und interne Finanzierungskosten widerspiegelt.

Hervorgehobene Risiken: (1) bis zu 100% Kapitalverlust, wenn die schlechteste Aktie >41% fällt; (2) keine Kupongarantie; (3) Kreditrisiko von CGMHI und Citigroup Inc.; (4) Liquiditätsrisiko – keine Börsennotierung, sekundärer Handel nur nach Ermessen über CGMI; (5) mögliche Interessenkonflikte, da CGMI Emittent, Underwriter, Berechnungsstelle und Hedger ist; (6) komplexe US-Steuerbehandlung und mögliche 30% Quellensteuer für Nicht-US-Investoren; (7) geschätzter Wert und Sekundärkurs wahrscheinlich deutlich unter Ausgabepreis wegen Absicherungskosten und Geld-Brief-Spanne.

Für Anleger, die eine höhere Rendite als bei einfachen Citigroup Senior Bonds suchen, bietet die Note ein zweistelliges Einkommen und einen 41% Abwärtspuffer, allerdings nur unter Übernahme von korreliertem Einzelaktienrisiko, Autocall-Kürzungsrisiko und Emittenten-Kreditrisiko. Das Wertpapier ist daher ausschließlich für erfahrene Anleger geeignet, die Aktienmarktvolatilität und Illiquidität für bis zu 18 Monate tolerieren können.

Positive
  • Double-digit potential yield (≥10.25% p.a.) provides significantly higher income than comparable conventional Citi senior debt with similar tenor.
  • 41% downside buffer protects principal unless the worst-performing share falls below 59% of its initial level.
  • Catch-up feature allows previously missed coupons to be recovered if the barrier is later met.
  • Early autocall returns capital quickly in strong equity scenarios, reducing duration risk.
Negative
  • Full principal at risk; worst-performing share drop below 59% leads to share delivery worth less than $1,000, potentially zero.
  • Conditional income; coupons skipped whenever the barrier is breached may result in no yield for entire term.
  • Issuer and guarantor credit risk; repayment depends on Citigroup Global Markets Holdings Inc. and Citigroup Inc. performance.
  • Illiquidity; no exchange listing and discretionary secondary market likely at steep discount to issue price.
  • Structuring cost; estimated value (≥$928.50) materially below $1,000 issue price, creating an immediate mark-to-market drag.
  • Complex taxation; uncertain U.S. federal tax treatment and possible 30% withholding for non-U.S. holders.
  • Autocall limits upside; strong share performance results in early redemption, capping total return.

Insights

TL;DR: High coupon & 41% buffer attractive, but principal is fully at risk and coupons are conditional; product suits yield-seeking, risk-tolerant buyers.

The note embeds a worst-of two-stock digital coupon and physical share settlement put option. The 10.25% headline yield is financed by selling downside beyond 41% and by giving Citigroup cheap call optionality via the autocall. Volatility and low correlation between AVGO and PANW increase skip-coupon probability and decrease expected return vs. headline. The indicative value (~$928.50) implies a c.7.2% structuring/hedging spread versus issue price, so investors transfer that economic edge to Citi on day one. Because the securities are senior debt, any deterioration in Citi’s credit spreads will erode secondary pricing even if stocks are flat. Overall impact for investors: risk-reward balanced toward yield seekers; for Citigroup equity investors: immaterial.

TL;DR: Product adds incremental, but immaterial, funding for Citigroup; buyers face layered credit, market and liquidity risks.

CGMHI achieves sub-institutional funding at a spread tighter than comparable senior notes by embedding equity-linked features. From a treasury standpoint, issuance is routine and not transformative, hence neutral to Citigroup credit metrics. For noteholders, the multiple underlyings amplify tail risk: only one stock needs to breach the 59% floor to trigger share delivery. Historical 10-year drawdowns show AVGO at –55% and PANW at –66%, both inside the loss zone. Illiquidity is significant: no listing, CGMI sole dealer, three-month bid premium decay. Tax complexity (Section 871(m) uncertainty) creates withholding risk for non-U.S. investors. Rating: neutral overall.

Citigroup Global Markets Holdings Inc. (garantita da Citigroup Inc.) sta promuovendo una nuova nota strutturata: “Titoli azionari collegati a un coupon contingente autocallable legati alla performance peggiore tra Broadcom Inc. (AVGO) e Palo Alto Networks Inc. (PANW), con scadenza 26 gennaio 2027.” Le obbligazioni senior non garantite denominate $1.000 offrono un tasso di coupon contingente di almeno il 10,25% annuo (pagato trimestralmente con almeno il 2,5625% per periodo), ma solo se, alla data di valutazione rilevante, l’azione con la performance peggiore chiude a o sopra la soglia di coupon pari al 59% del valore iniziale. I coupon saltati possono essere recuperati se successivamente la soglia viene raggiunta, ma quelli persi alla valutazione finale sono definitivamente persi.

Il rimborso del capitale è condizionato. Se i titoli non vengono richiamati automaticamente, alla scadenza i possessori ricevono:

  • $1.000 più il coupon finale se l’azione peggiore è ≥ al valore di buffer finale (anch’esso il 59% del valore iniziale).
  • Un numero fisso di azioni della peggiore performance (o equivalente in contanti) se il valore finale è <59% del valore iniziale. Questo potrebbe valere molto meno di $1.000 e potenzialmente zero se il prezzo dell’azione crolla.

Il rimborso anticipato automatico (autocall) è possibile in cinque date trimestrali a partire dal 16 ottobre 2025 se l’azione peggiore è ≥ al valore iniziale; in tal caso gli investitori ricevono $1.000 più il coupon dovuto, terminando anticipatamente l’investimento e limitando il potenziale di guadagno.

Termini iniziali chiave (aggiornati al 10 luglio 2025): AVGO iniziale $275,40, PANW iniziale $192,07; livelli di coupon e buffer fissati al 59% per entrambi. Il valore stimato preliminare alla data di pricing è atteso ≥ $928,50, inferiore al prezzo di emissione di $1.000, riflettendo commissioni di distribuzione ($12,50) e spread di finanziamento interno.

Rischi evidenziati: (1) perdita fino al 100% del capitale se la peggiore azione scende oltre il 41%; (2) nessuna garanzia di coupon; (3) rischio di credito di CGMHI e Citigroup Inc.; (4) rischio di liquidità – nessuna quotazione in borsa e mercato secondario discrezionale solo tramite CGMI; (5) potenziali conflitti di interesse poiché CGMI è emittente, sottoscrittore, agente di calcolo e copertura; (6) trattamento fiscale USA complesso e possibile ritenuta del 30% per investitori non USA; (7) valore stimato e prezzo di mercato secondario probabilmente molto inferiori al prezzo di emissione a causa di costi di copertura e spread denaro-lettera.

Per gli investitori che cercano un rendimento superiore rispetto al debito senior plain-vanilla di Citigroup, la nota offre un potenziale di reddito a doppia cifra e un buffer di downside del 41%, ma solo assumendo rischi correlati a singole azioni, rischio di richiamo anticipato e rischio di credito dell’emittente. Il titolo è quindi adatto esclusivamente a investitori sofisticati in grado di tollerare volatilità azionaria e illiquidità per un periodo fino a 18 mesi.

Citigroup Global Markets Holdings Inc. (garantizado por Citigroup Inc.) está comercializando una nueva nota estructurada: “Valores ligados a acciones con cupón contingente autocancelable vinculados al peor desempeño entre Broadcom Inc. (AVGO) y Palo Alto Networks Inc. (PANW), con vencimiento el 26 de enero de 2027.” Los bonos senior no garantizados denominados en $1,000 ofrecen una tasa de cupón contingente de al menos 10.25% anual (pagada trimestralmente con ≥2.5625% por periodo), pero solo si, en la fecha de valoración correspondiente, la acción con peor desempeño cierra en o por encima de la barrera de cupón del 59% de su nivel inicial. Los cupones omitidos pueden recuperarse si la barrera se cumple posteriormente, pero los cupones no pagados en la valoración final se pierden permanentemente.

El reembolso del principal es condicional. Si los valores no son llamados automáticamente, los tenedores reciben al vencimiento:

  • $1,000 más el cupón final si la acción con peor desempeño está ≥ a su valor de buffer final (también 59% del inicial).
  • Un número fijo de acciones con peor desempeño (o equivalente en efectivo) si el nivel final es <59% del inicial. Esto puede valer mucho menos de $1,000 y podría ser $0 si el precio de la acción colapsa.

Redención anticipada automática (autocall) es posible en cualquiera de cinco fechas trimestrales a partir del 16 de octubre de 2025 si la acción con peor desempeño está ≥ a su nivel inicial; los inversionistas reciben entonces $1,000 más el cupón debido, terminando la operación anticipadamente y limitando el potencial de ganancia.

Términos iniciales clave (establecidos el 10 de julio de 2025): AVGO inicial $275.40, PANW inicial $192.07; niveles de cupón/barrera fijados en 59% para ambos. El valor estimado preliminar en la fecha de fijación de precio se espera sea ≥$928.50, por debajo del precio de emisión de $1,000, reflejando comisiones de distribución ($12.50) y el diferencial interno de financiamiento.

Riesgos destacados: (1) pérdida de capital hasta del 100% si el peor desempeño cae más del 41%; (2) sin garantía de cupón alguno; (3) riesgo crediticio de CGMHI y Citigroup Inc.; (4) riesgo de liquidez – sin cotización en bolsa y mercado secundario discrecional solo a través de CGMI; (5) posibles conflictos de interés ya que CGMI es emisor, suscriptor, agente de cálculo y coberturista; (6) tratamiento fiscal estadounidense complejo y posible retención del 30% para inversores no estadounidenses; (7) valor estimado y oferta secundaria probablemente muy por debajo del precio de emisión debido a costos de cobertura y diferencial de compra-venta.

Para inversores que buscan un rendimiento mejorado respecto a la deuda senior plain-vanilla de Citigroup, la nota ofrece potencial de ingreso de dos dígitos y un buffer de caída del 41%, pero solo asumiendo riesgos correlacionados con acciones individuales, riesgo de truncamiento por autocall y exposición al crédito del emisor. Por lo tanto, el título es adecuado únicamente para inversores sofisticados capaces de tolerar volatilidad a nivel de acciones e iliquidez por hasta 18 meses.

Citigroup Global Markets Holdings Inc. (Citigroup Inc. 보증)는 새로운 구조화 채권을 마케팅하고 있습니다: “Broadcom Inc.(AVGO)와 Palo Alto Networks Inc.(PANW) 중 최저 성과 주식에 연동된 자가상환형 조건부 쿠폰 주식 연계 증권, 만기 2027년 1월 26일.” $1,000 단위의 선순위 무담보 채권은 최소 연 10.25%의 조건부 쿠폰율(분기별 ≥2.5625% 지급)을 제공하지만, 해당 평가일에 최저 성과 주식이 초기 가격의 59%인 쿠폰 장벽 이상으로 마감할 경우에만 지급됩니다. 지급이 누락된 쿠폰은 이후 장벽 충족 시 회복 가능하지만, 최종 평가 시 누락된 쿠폰은 영구적으로 상실됩니다.

원금 상환은 조건부입니다. 증권이 자동 상환되지 않을 경우 만기 시 보유자는 다음을 받습니다:

  • 최저 성과 주식이 최종 버퍼 값(초기 가격의 59%) 이상일 경우 $1,000와 최종 쿠폰.
  • 최종 가격이 초기 가격의 59% 미만일 경우 최저 성과 주식 일정 수량(또는 현금 상당액). 이는 $1,000보다 훨씬 적을 수 있으며 주가 폭락 시 0이 될 수도 있습니다.

자가상환(오토콜)은 2025년 10월 16일부터 시작되는 5회 분기별 날짜 중 어느 날에나 가능하며, 최저 성과 주식이 초기 가격 이상일 경우 투자자는 $1,000과 해당 쿠폰을 받아 조기 종료되고 상승 잠재력은 제한됩니다.

주요 초기 조건(2025년 7월 10일 기준): AVGO 초기 $275.40, PANW 초기 $192.07; 쿠폰/버퍼 수준은 각각 59%로 고정. 가격 책정일의 예비 추정 가치는 $928.50 이상으로 예상되며, 이는 발행가 $1,000보다 낮습니다. 이는 배포 수수료($12.50)와 내부 자금 조달 스프레드를 반영한 것입니다.

강조된 위험: (1) 최저 성과 주식이 41% 이상 하락 시 최대 100% 자본 손실 가능; (2) 쿠폰 지급 보장 없음; (3) CGMHI 및 Citigroup Inc.의 신용 위험; (4) 유동성 위험 – 거래소 상장 없음, CGMI를 통한 임의의 2차 시장만 존재; (5) CGMI가 발행인, 인수인, 계산 대리인 및 헤지 담당자로서 잠재적 이해 상충; (6) 복잡한 미국 세금 처리 및 미국 외 투자자에 대한 30% 원천징수 가능성; (7) 헤지 비용 및 매수-매도 스프레드로 인해 추정 가치 및 2차 매도 호가가 발행가보다 훨씬 낮을 가능성.

평범한 Citigroup 선순위 채권 대비 수익률 향상을 원하는 투자자에게 이 노트는 두 자릿수 수익 잠재력과 41% 하락 방어막을 제공하지만, 단일 주식 관련 위험, 자동 상환 조기 종료 위험 및 발행인 신용 위험을 감수해야 합니다. 따라서 본 증권은 최대 18개월 동안 주식 수준의 변동성과 유동성 부족을 견딜 수 있는 숙련된 투자자에게만 적합합니다.

Citigroup Global Markets Holdings Inc. (garantie par Citigroup Inc.) commercialise une nouvelle note structurée : « Titres liés à des actions avec coupon conditionnel autocallable liés à la pire performance entre Broadcom Inc. (AVGO) et Palo Alto Networks Inc. (PANW), échéance 26 janvier 2027. » Les notes senior non garanties, d’une valeur nominale de 1 000 $, offrent un taux de coupon conditionnel d’au moins 10,25 % par an (payé trimestriellement à ≥2,5625 % par période), mais uniquement si, à la date d’évaluation pertinente, l’action la moins performante clôture à ou au-dessus de sa barrière de coupon fixée à 59 % de son niveau initial. Les coupons non versés peuvent être récupérés si la barrière est ensuite atteinte, mais les coupons manqués lors de l’évaluation finale sont définitivement perdus.

Le remboursement du capital est conditionnel. Si les titres ne sont pas automatiquement rappelés, les détenteurs reçoivent à l’échéance :

  • 1 000 $ plus le coupon final si l’action la moins performante est ≥ à sa valeur tampon finale (également 59 % du niveau initial).
  • Un nombre fixe d’actions de la pire performance (ou équivalent en espèces) si le niveau final est <59 % du niveau initial. Cela peut valoir bien moins que 1 000 $ et pourrait être nul si le cours de l’action s’effondre.

Le remboursement anticipé automatique (autocall) est possible à l’une des cinq dates trimestrielles à partir du 16 octobre 2025 si l’action la moins performante est ≥ à son niveau initial ; les investisseurs reçoivent alors 1 000 $ plus le coupon dû, mettant fin prématurément à l’opération et limitant le potentiel de gain.

Principaux termes initiaux (fixés au 10 juillet 2025) : AVGO initial 275,40 $, PANW initial 192,07 $ ; niveaux de coupon / tampon fixés à 59 % chacun. La valeur estimée préliminaire à la date de tarification devrait être ≥ 928,50 $, inférieure au prix d’émission de 1 000 $, reflétant les frais de distribution (12,50 $) et l’écart de financement interne.

Risques mis en avant : (1) perte en capital pouvant atteindre 100 % si la pire action chute de plus de 41 % ; (2) aucune garantie de coupon ; (3) risque de crédit de CGMHI et Citigroup Inc. ; (4) risque de liquidité – pas de cotation en bourse et marché secondaire discrétionnaire uniquement via CGMI ; (5) conflits potentiels d’intérêts car CGMI est émetteur, souscripteur, agent de calcul et couverturiste ; (6) traitement fiscal américain complexe et retenue à la source possible de 30 % pour les investisseurs non américains ; (7) valeur estimée et prix secondaire probablement bien inférieurs au prix d’émission en raison des coûts de couverture et du spread acheteur-vendeur.

Pour les investisseurs recherchant un rendement supérieur à celui de la dette senior classique de Citigroup, la note offre un potentiel de revenu à deux chiffres et une protection à la baisse de 41 %, mais uniquement en assumant un risque d’action individuelle corrélé, un risque de réduction par autocall et une exposition au risque de crédit de l’émetteur. Le titre est donc adapté uniquement aux investisseurs avertis capables de tolérer une volatilité au niveau des actions et une illiquidité pouvant durer jusqu’à 18 mois.

Citigroup Global Markets Holdings Inc. (garantiert von Citigroup Inc.) bringt eine neue strukturierte Note auf den Markt: „Autocallable Contingent Coupon Equity-Linked Securities, die an die schlechteste Performance von Broadcom Inc. (AVGO) und Palo Alto Networks Inc. (PANW) gekoppelt sind, Fälligkeit 26. Januar 2027.“ Die unbesicherten Senior Notes mit Nennwert $1.000 bieten einen bedingten Kupon von mindestens 10,25% p.a. (vierteljährlich gezahlt mit ≥2,5625% pro Periode), aber nur, wenn der Kurs der schlechtesten Aktie am jeweiligen Bewertungstag auf oder über der Kupon-Schwelle von 59% des Anfangswerts schließt. Ausgefallene Kupons können nachgeholt werden, falls die Schwelle später erreicht wird, bei endgültiger Bewertung verfallene Kupons sind jedoch dauerhaft verloren.

Die Rückzahlung des Kapitals ist bedingt. Werden die Wertpapiere nicht automatisch zurückgerufen, erhalten die Inhaber bei Fälligkeit:

  • $1.000 plus den letzten Kupon, wenn die schlechteste Aktie ≥ dem finalen Pufferwert (ebenfalls 59% des Anfangswerts) ist.
  • Eine feste Anzahl der schlechtesten Aktien (oder Baräquivalent), wenn der Endkurs <59% des Anfangswerts ist. Dieser Wert kann deutlich unter $1.000 liegen und bei einem Kurssturz sogar null betragen.

Automatische vorzeitige Rückzahlung (Autocall) ist an fünf vierteljährlichen Terminen ab dem 16. Oktober 2025 möglich, wenn die schlechteste Aktie ≥ dem Anfangswert ist; Anleger erhalten dann $1.000 plus den fälligen Kupon, wodurch das Investment vorzeitig endet und die Gewinnchancen begrenzt werden.

Wichtige Anfangsbedingungen (Stand 10. Juli 2025): AVGO Anfang $275,40, PANW Anfang $192,07; Kupon- und Pufferlevel sind jeweils auf 59% fixiert. Der vorläufig geschätzte Wert am Pricing-Tag wird voraussichtlich ≥$928,50 betragen, unter dem Ausgabepreis von $1.000, was Vertriebsgebühren ($12,50) und interne Finanzierungskosten widerspiegelt.

Hervorgehobene Risiken: (1) bis zu 100% Kapitalverlust, wenn die schlechteste Aktie >41% fällt; (2) keine Kupongarantie; (3) Kreditrisiko von CGMHI und Citigroup Inc.; (4) Liquiditätsrisiko – keine Börsennotierung, sekundärer Handel nur nach Ermessen über CGMI; (5) mögliche Interessenkonflikte, da CGMI Emittent, Underwriter, Berechnungsstelle und Hedger ist; (6) komplexe US-Steuerbehandlung und mögliche 30% Quellensteuer für Nicht-US-Investoren; (7) geschätzter Wert und Sekundärkurs wahrscheinlich deutlich unter Ausgabepreis wegen Absicherungskosten und Geld-Brief-Spanne.

Für Anleger, die eine höhere Rendite als bei einfachen Citigroup Senior Bonds suchen, bietet die Note ein zweistelliges Einkommen und einen 41% Abwärtspuffer, allerdings nur unter Übernahme von korreliertem Einzelaktienrisiko, Autocall-Kürzungsrisiko und Emittenten-Kreditrisiko. Das Wertpapier ist daher ausschließlich für erfahrene Anleger geeignet, die Aktienmarktvolatilität und Illiquidität für bis zu 18 Monate tolerieren können.


Filed Pursuant to Rule 424(b)(3)

Registration No. 333-287582

PROSPECTUS SUPPLEMENT NO. 7

(to prospectus dated May 29, 2025)

Medicus Pharma Ltd.

Up to 3,710,000 Common Shares


This prospectus supplement amends and supplements the prospectus dated May 29, 2025, as supplemented or amended from time to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-287582). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 14, 2025 (the "Form 8-K"). Accordingly, we have attached the Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common shares are listed on The Nasdaq Capital Market ("Nasdaq") under the symbol "MDCX". On July 11, 2025, the last reported sales price of the common shares was $3.03.

We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" beginning on page 9 of the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.

None of the Securities and Exchange Commission, any state securities commission or the securities commission of any Canadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or the Prospectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is July 14, 2025.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario 001-42408 98-1778211
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbols   Name of each exchange on which registered
Common shares, no par value   MDCX   NASDAQ Capital Market
Warrants, each exercisable for one common share at an exercise price of $4.64 per share   MDCXW   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 1.01. Entry into a Material Definitive Agreement.

Warrant Inducement Agreement

On July 14, 2025, Medicus Pharma Ltd. (the "Company") entered into an inducement offer (the "Agreement") with a certain accredited and institutional holder (the "Holder") to exercise existing warrants to purchase up to 1,340,000 of the Company's common shares ("Common Shares") issued on March 10, 2025 and with an exercise price of $2.80 per Common Share (the "Existing Warrants"). Pursuant to the Agreement, the Holder, upon exercise, will receive new unregistered warrants (the "New Warrants") to purchase up to 2,680,000 Common Shares upon the exercise of the New Warrants (the "New Warrant Shares"), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended ("Securities Act").

The New Warrants, which will be issued in two series, each containing 50% of the New Warrants, will have an exercise price of $3.75 per Common Share, will be exercisable following the date of issuance and will expire on the five-year anniversary of such date. In addition, one of the series of New Warrants will contain a right for the Company to force the Holder to exercise such New Warrants, subject to certain conditions described in the New Warrants, in the event that the average VWAP of the Common Shares during any ten (10) Trading Day period shall equal or exceed $10.00. The exercise price and the number of New Warrant Shares issuable upon exercise of each New Warrant are subject to appropriate adjustments in the event of certain share dividends and distributions, share splits, share consolidations, reclassifications or similar events affecting the Common Shares. In addition, in certain circumstances, upon a fundamental transaction (as defined in the New Warrants), a holder of New Warrants will be entitled to receive, upon exercise of the New Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the New Warrants immediately prior to the fundamental transaction. Additionally, as more fully described in the New Warrants, in the event of certain fundamental transactions, the holders of the New Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the New Warrants on the date of consummation of the transaction.

The closing is expected to take place on or about July 14, 2025, subject to satisfaction of customary closing conditions. Gross proceeds to the Company from the exercise of the Existing Warrants is expected to be approximately $3.75 million, prior to deducting placement agent fees as further described below. The Company intends to use the net proceeds from the offering for ongoing clinical trials, working capital and general corporate purposes, which includes costs associated with the Company's agreement to acquire Antev Limited.

The issuance of the Common Shares underlying the Existing Warrants will be qualified pursuant to the Company's Offering Statement on Form 1-A (File No. 024-12573).

The Company agreed in the Agreement to file a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") providing for the resale of the New Warrant Shares as soon as practicable, and in any event within one-hundred and twenty (120) calendar days of the date of the Agreement (the "Initial Filing Date), and to use commercially reasonable efforts to have such registration statement declared effective by the SEC on or prior to the thirtieth (30) calendar day after the Initial Filing Date. Pursuant to the Agreement, the Company shall use commercially reasonable efforts to keep such registration statement effective at all times until the original holder of the New Warrants may sell its New Warrant Shares without volume or manner of sale limitation under Rule 144.


In connection with the transactions contemplated in the Agreement, the Company agreed to pay its inducement agent, Maxim Group, LLC, a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated by the Agreement.

The foregoing descriptions of the New Warrants and Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the New Warrants and the Agreement, forms of which are attached to this Current Report on Form 8-K as Exhibits 4.1 and 10.1, respectively.

Item 3.02 Unregistered Sales of Equity Securities.

The disclosure regarding the Existing Warrants, New Warrants and the New Warrant Shares set forth under Item 1.01 is incorporated by reference into this Item 3.02. The Company expects to issue the New Warrants in reliance on the exemption from the registration requirements of the Securities Act, provided by Section 4(a)(2) under the Securities Act in a transaction not involving a public offering. Neither the New Warrants nor the New Warrant Shares have been registered under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

In addition, on July 9, 2025 and July 14, 2025, pursuant to the previously disclosed Standby Equity Purchase Agreement (the "SEPA") dated February 10, 2025 between Medicus Pharma Ltd. (the "Company") and YA II PN, Ltd. ("Yorkville"), the Company sold 155,000 Common Shares to Yorkville for approximately $3.2841 per share, or approximately $509,000 in consideration and 335,000 Common Shares to Yorkville for approximately $3.0216 per share, or approximately $1,012,000 in consideration, respectively (together, the "SEPA Advances"). The Company sold, in the aggregate, 490,000 Common Shares to Yorkville through the SEPA Advances and received aggregate net proceeds of approximately $1,521,000. The Company may cause Yorkville to purchase additional Common Shares under the SEPA from time to time, subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA. The Company intends to use part of the net proceeds from the SEPA Advances to prepay a portion of the debentures the Company has outstanding with Yorkville, as described in that certain Current Report on Form 8-K dated June 20, 2025. The Common Shares were issued and sold to Yorkville in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act") afforded by Section 4(a)(2) of the Securities Act. The Company is relying on this exemption from registration based in part on representations made by Yorkville in the SEPA. Yorkville may resell the Common Shares it has purchased from the Company under the SEPA from time to time pursuant to that certain effective registration statement on form S-1 (File No. 333-287582), which has been filed by the Company in accordance with its requirements under the SEPA.

This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.
Description
4.1 Form of New Warrant
10.1 Form of Warrant Inducement Agreement
104.1 Cover Page Interactive Data File (embedded within the inline XBRL document).


Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the closing of the Company's issuance of the New Warrants and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the Antev transaction, including the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

  MEDICUS PHARMA LTD.
     
  By:   /s/ Raza Bokhari
  Name:   Dr. Raza Bokhari
  Title:   Executive Chairman and Chief Executive Officer

Dated: July 14, 2025​​


FAQ

What coupon does the Citigroup (C) autocallable note pay?

It offers a contingent coupon of at least 10.25% per annum, paid quarterly at ≥2.5625% of principal, but only if the worst-performing share closes ≥59% of its initial value on the relevant valuation date.

How much principal protection is provided by the note?

There is a 41% buffer; if the worst-performing share stays at or above 59% of its initial level on the final valuation date, investors receive full $1,000. Below that, principal converts to shares and losses mirror the stock’s decline.

When can the securities be called early?

On any of the five quarterly valuation dates from 16 Oct 2025 to 16 Oct 2026, if the worst-performing share is at or above its initial level, the note is automatically redeemed for $1,000 plus the due coupon.

What is the estimated value versus the issue price?

Citigroup expects an estimated value of at least $928.50 per $1,000 note on the pricing date, reflecting structuring and hedging costs; the issue price is $1,000.

Are the notes listed on an exchange?

No. They will not be listed; secondary liquidity relies solely on Citigroup Global Markets Inc. making a market at its discretion.

What underlying stocks determine performance?

Broadcom Inc. (AVGO) and Palo Alto Networks Inc. (PANW); the note’s payments are based on the worst performer of the two.

What are the main risks investors should consider?

Principal loss if the buffer is broken, missed coupons when barriers are not met, credit risk of Citi, illiquidity, and complex tax treatment including possible withholding for non-U.S. holders.
Medicus Pharma Ltd

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data

47.64M
8.82M
Pharmaceutical Preparations
W. CONSHOHOCKEN